Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YVR
|
|||
| Former ID |
DPR000150
|
|||
| Drug Name |
Oxamflatin
|
|||
| Synonyms |
NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H14N2O4S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)C#CC=CC(=O)NO
|
|||
| InChI |
1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+
|
|||
| InChIKey |
QRPSQQUYPMFERG-LFYBBSHMSA-N
|
|||
| CAS Number |
CAS 151720-43-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11651402, 12015067, 14924949, 26759301, 29217613, 39379766, 48428190, 52944410, 57361597, 76715576, 99375465, 104026127, 113909785, 121379644, 131299952, 135360538, 142692368, 152039134, 162248411, 163687550, 164763887, 175608107, 177748467, 188919917, 204362425, 227462876, 227462878, 242084443, 250136914, 252355618, 252468845
|
|||
| ChEBI ID |
CHEBI:93779
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007547) | |||
| REF 2 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | |||
| REF 3 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.